ScripThe second quarter ended with a significant decline in venture capital financings from the prior quarter, driven by a sharp drop in mega-rounds of $100m or more. All hope was not lost in Q2, however,
ScripThe capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir
Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
ScripThe pharmaceutical, biotech and other allied industries came together in London on 4 December to celebrate another year of exceptional achievement at the 20th Annual Scrip Awards at the Raffles hotel